Insulet Q2 revenue beats on higher Omnipod sales
Insulet Q2 revenue beats on higher Omnipod sales
Overview
Medical device maker's Q2 revenue rose 23.5%, beating analyst expectations
Adjusted EPS for Q2 rose 41.5% year-over-year
Q2 net income increased but missed analyst expectations
Outlook
Company lowers FY 2026 U.S. Omnipod revenue growth forecast to 17%-19% from 20%-22%
Insulet raises FY 2026 international Omnipod revenue growth forecast to 30%-32% from 26%-28%
Company expects FY 2026 adjusted EPS growth above 25% and adjusted operating margin to expand ~100 bps
Result Drivers
OMNIPOD SALES - Co said broad-based growth in Omnipod product sales, especially internationally, drove Q2 revenue increase
PRODUCT LAUNCHES - Launch of Omnipod 5 and Omnipod Discover in Spain expanded access to tubeless diabetes technology
TECHNOLOGY ENHANCEMENTS - Co expanded Omnipod 5 ecosystem with next-generation algorithm and broader sensor compatibility
Company press release: ID:nBw4Lv3vQa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $801.70 mln | $787.23 mln (22 Analysts) |
Q2 EPS |
| $1.37 |
|
Q2 Net Income | Miss | $95 mln | $101.81 mln (21 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Insulet Corporation is $241.00, about 44.5% above its August 4 closing price of $166.82
The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 25 three months ago
Reuters Recommended Reads
Aug 5 - Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong
Aug 5 - UK's LivaNova Q2 revenue beats estimates; lifts 2026 outlook
Aug 3 - KKR to take medical-equipment maker Integer Holdings private in $5.7 billion deal
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)